PTEN is mutated in 8.03% of malignant solid tumor patients [3].

PTEN is an inclusion criterion in 29 clinical trials for malignant solid tumor, of which 24 are open and 5 are closed. Of the trials that contain PTEN status and malignant solid tumor as inclusion criteria, 13 are phase 1 (9 open), 4 are phase 1/phase 2 (3 open), 11 are phase 2 (11 open), and 1 is phase 4 (1 open) [4].

Olaparib, adavosertib, and capivasertib are the most frequent therapies in malignant solid tumor trials with PTEN alterations as inclusion criteria [4].

PTEN is mutated in 6.83% of breast carcinoma patients [3].

PTEN is an inclusion criterion in 18 clinical trials for breast carcinoma, of which 16 are open and 2 are closed. Of the trials that contain PTEN status and breast carcinoma as inclusion criteria, 7 are phase 1 (6 open), 2 are phase 1/phase 2 (1 open), 7 are phase 2 (7 open), 1 is phase 2/phase 3 (1 open), and 1 is phase 3 (1 open) [4].

Paclitaxel, olaparib, and cyclophosphamide are the most frequent therapies in breast carcinoma trials with PTEN alterations as inclusion criteria [4].

PTEN is mutated in 16.44% of prostate adenocarcinoma patients [3].

PTEN is an inclusion criterion in 9 clinical trials for prostate adenocarcinoma, of which 9 are open and 0 are closed. Of the trials that contain PTEN status and prostate adenocarcinoma as inclusion criteria, 9 are phase 2 (9 open) [4].

Carboplatin, rucaparib, and testosterone enanthate are the most frequent therapies in prostate adenocarcinoma trials with PTEN alterations as inclusion criteria [4].

PTEN is mutated in 3.58% of non-small cell lung carcinoma patients [3].

PTEN is an inclusion criterion in 9 clinical trials for non-small cell lung carcinoma, of which 6 are open and 3 are closed. Of the trials that contain PTEN status and non-small cell lung carcinoma as inclusion criteria, 2 are phase 1 (0 open), 4 are phase 1/phase 2 (3 open), and 3 are phase 2 (3 open) [4].

Selumetinib, akt inhibitor mk2206, and gsk2636771 are the most frequent therapies in non-small cell lung carcinoma trials with PTEN alterations as inclusion criteria [4].

PTEN is mutated in 16.51% of prostate carcinoma patients [3].

PTEN is an inclusion criterion in 8 clinical trials for prostate carcinoma, of which 7 are open and 1 is closed. Of the trials that contain PTEN status and prostate carcinoma as inclusion criteria, 3 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (3 open), and 1 is phase 3 (1 open) [4].

Gsk2636771, azd8186, and parp inhibitor bgb-290 are the most frequent therapies in prostate carcinoma trials with PTEN alterations as inclusion criteria [4].

PTEN is mutated in 4.55% of ovarian carcinoma patients [3].

PTEN is an inclusion criterion in 7 clinical trials for ovarian carcinoma, of which 5 are open and 2 are closed. Of the trials that contain PTEN status and ovarian carcinoma as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), 2 are phase 2 (2 open), and 1 is phase 3 (0 open) [4].

Olaparib, gsk2636771, and parp inhibitor bgb-290 are the most frequent therapies in ovarian carcinoma trials with PTEN alterations as inclusion criteria [4].

PTEN is mutated in 42.67% of endometrial carcinoma patients [3].

PTEN is an inclusion criterion in 5 clinical trials for endometrial carcinoma, of which 3 are open and 2 are closed. Of the trials that contain PTEN status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (0 open), 2 are phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [4].

Gsk2636771, pi3k/mtor inhibitor ly3023414, and vistusertib are the most frequent therapies in endometrial carcinoma trials with PTEN alterations as inclusion criteria [4].

PTEN is mutated in 6.31% of head and neck squamous cell carcinoma patients [3].

PTEN is an inclusion criterion in 5 clinical trials for head and neck squamous cell carcinoma, of which 3 are open and 2 are closed. Of the trials that contain PTEN status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (0 open), 2 are phase 1/phase 2 (2 open), and 2 are phase 2 (1 open) [4].

Gsk2636771, sra737, and abemaciclib are the most frequent therapies in head and neck squamous cell carcinoma trials with PTEN alterations as inclusion criteria [4].

PTEN is mutated in 3.86% of colorectal carcinoma patients [3].

PTEN is an inclusion criterion in 5 clinical trials for colorectal carcinoma, of which 3 are open and 2 are closed. Of the trials that contain PTEN status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (0 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 3 (1 open) [4].

Gsk2636771, sra737, and vistusertib are the most frequent therapies in colorectal carcinoma trials with PTEN alterations as inclusion criteria [4].

PTEN is mutated in 8.29% of melanoma patients [3].

PTEN is an inclusion criterion in 4 clinical trials for melanoma, of which 2 are open and 2 are closed. Of the trials that contain PTEN status and melanoma as inclusion criteria, 2 are phase 1 (0 open) and 2 are phase 1/phase 2 (2 open) [4].

Gsk2636771, vistusertib, and selumetinib are the most frequent therapies in melanoma trials with PTEN alterations as inclusion criteria [4].

PTEN is mutated in 6.31% of non-hodgkin lymphoma patients [3].

PTEN is an inclusion criterion in 4 clinical trials for non-hodgkin lymphoma, of which 4 are open and 0 are closed. Of the trials that contain PTEN status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [4].

Pi3k/mtor inhibitor ly3023414, letrozole, and tazemetostat are the most frequent therapies in non-hodgkin lymphoma trials with PTEN alterations as inclusion criteria [4].

PTEN is mutated in 37.23% of glioblastoma patients [3].

PTEN is an inclusion criterion in 3 clinical trials for glioblastoma, of which 1 is open and 2 are closed. Of the trials that contain PTEN status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 1/phase 2 (1 open) [4].

Gsk2636771, atezolizumab, and ipatasertib are the most frequent therapies in glioblastoma trials with PTEN alterations as inclusion criteria [4].

PTEN is mutated in 11.16% of squamous cell lung carcinoma patients [3].

PTEN is an inclusion criterion in 3 clinical trials for squamous cell lung carcinoma, of which 3 are open and 0 are closed. Of the trials that contain PTEN status and squamous cell lung carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [4].

Vistusertib, azd8186, and pi3k/mtor inhibitor ly3023414 are the most frequent therapies in squamous cell lung carcinoma trials with PTEN alterations as inclusion criteria [4].

PTEN is mutated in 11.05% of small cell lung carcinoma patients [3].

PTEN is an inclusion criterion in 3 clinical trials for small cell lung carcinoma, of which 3 are open and 0 are closed. Of the trials that contain PTEN status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [4].

Akt inhibitor mk2206, parp inhibitor bgb-290, and erlotinib are the most frequent therapies in small cell lung carcinoma trials with PTEN alterations as inclusion criteria [4].

PTEN is mutated in 1.07% of pancreatic adenocarcinoma patients [3].

PTEN is an inclusion criterion in 3 clinical trials for pancreatic adenocarcinoma, of which 3 are open and 0 are closed. Of the trials that contain PTEN status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [4].

Olaparib, parp inhibitor bgb-290, and tislelizumab are the most frequent therapies in pancreatic adenocarcinoma trials with PTEN alterations as inclusion criteria [4].

PTEN is mutated in 0.73% of cancer patients [3].

PTEN is an inclusion criterion in 3 clinical trials for cancer, of which 2 are open and 1 is closed. Of the trials that contain PTEN status and cancer as inclusion criteria, 1 is early phase 1 (0 open), 1 is phase 1 (1 open), and 1 is phase 2 (1 open) [4].

Pi3k/mtor inhibitor ly3023414, abemaciclib, and cisplatin are the most frequent therapies in cancer trials with PTEN alterations as inclusion criteria [4].

PTEN is an inclusion criterion in 3 clinical trials for fallopian tube carcinoma, of which 2 are open and 1 is closed. Of the trials that contain PTEN status and fallopian tube carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 2 (1 open), and 1 is phase 3 (0 open) [4].

Parp inhibitor bgb-290, niraparib, and olaparib are the most frequent therapies in fallopian tube carcinoma trials with PTEN alterations as inclusion criteria [4].

PTEN is mutated in 8.95% of leiomyosarcoma patients [3].

PTEN is an inclusion criterion in 2 clinical trials for leiomyosarcoma, of which 2 are open and 0 are closed. Of the trials that contain PTEN status and leiomyosarcoma as inclusion criteria, 2 are phase 2 (2 open) [4].

Atr kinase inhibitor m6620 is the most frequent therapy in leiomyosarcoma trials with PTEN alterations as inclusion criteria [4].

PTEN is mutated in 3.91% of gastric adenocarcinoma patients [3].

PTEN is an inclusion criterion in 2 clinical trials for gastric adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain PTEN status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [4].

Gsk2636771 is the most frequent therapy in gastric adenocarcinoma trials with PTEN alterations as inclusion criteria [4].

PTEN is mutated in 2.16% of cholangiocarcinoma patients [3].

PTEN is an inclusion criterion in 2 clinical trials for cholangiocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain PTEN status and cholangiocarcinoma as inclusion criteria, 2 are phase 2 (2 open) [4].

Vistusertib, adavosertib, and capivasertib are the most frequent therapies in cholangiocarcinoma trials with PTEN alterations as inclusion criteria [4].

PTEN is an inclusion criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain PTEN status and multiple myeloma as inclusion criteria, 2 are phase 2 (2 open) [4].

Vismodegib, pertuzumab, and nivolumab are the most frequent therapies in multiple myeloma trials with PTEN alterations as inclusion criteria [4].

PTEN is an inclusion criterion in 2 clinical trials for primary peritoneal carcinoma, of which 1 is open and 1 is closed. Of the trials that contain PTEN status and primary peritoneal carcinoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 3 (0 open) [4].

Niraparib, olaparib, and placebo are the most frequent therapies in primary peritoneal carcinoma trials with PTEN alterations as inclusion criteria [4].

PTEN is mutated in 30.11% of malignant glioma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and malignant glioma as inclusion criteria, 1 is early phase 1 (1 open) [4].

Everolimus and ribociclib are the most frequent therapies in malignant glioma trials with PTEN alterations as inclusion criteria [4].

PTEN is mutated in 8.57% of myxofibrosarcoma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for myxofibrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and myxofibrosarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PTEN is mutated in 6.67% of B-cell non-hodgkin lymphoma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with PTEN alterations as inclusion criteria [4].

PTEN is mutated in 6.38% of clear cell renal cell carcinoma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for clear cell renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and clear cell renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

Niraparib is the most frequent therapy in clear cell renal cell carcinoma trials with PTEN alterations as inclusion criteria [4].

PTEN is mutated in 6.09% of renal cell carcinoma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and renal cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

Vistusertib and selumetinib are the most frequent therapies in renal cell carcinoma trials with PTEN alterations as inclusion criteria [4].

PTEN is mutated in 10.0% of pancreatic ductal adenocarcinoma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for pancreatic ductal adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains PTEN status and pancreatic ductal adenocarcinoma as inclusion criteria, 1 is phase 2 (0 open) [4].

PTEN is mutated in 10.0% of pleomorphic liposarcoma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for pleomorphic liposarcoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and pleomorphic liposarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PTEN is mutated in 5.03% of thyroid gland carcinoma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

Vistusertib and selumetinib are the most frequent therapies in thyroid gland carcinoma trials with PTEN alterations as inclusion criteria [4].

PTEN is mutated in 5.0% of malignant peripheral nerve sheath tumor patients [3].

PTEN is an inclusion criterion in 1 clinical trial for malignant peripheral nerve sheath tumor, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and malignant peripheral nerve sheath tumor as inclusion criteria, 1 is phase 2 (1 open) [4].

PTEN is mutated in 5.73% of undifferentiated pleomorphic sarcoma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for undifferentiated pleomorphic sarcoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and undifferentiated pleomorphic sarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PTEN is mutated in 3.42% of gastric carcinoma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

Parp inhibitor bgb-290 and tislelizumab are the most frequent therapies in gastric carcinoma trials with PTEN alterations as inclusion criteria [4].

PTEN is mutated in 3.45% of urothelial carcinoma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

Parp inhibitor bgb-290 and tislelizumab are the most frequent therapies in urothelial carcinoma trials with PTEN alterations as inclusion criteria [4].

PTEN is mutated in 2.56% of angiosarcoma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for angiosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and angiosarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PTEN is mutated in 4.16% of soft tissue sarcoma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PTEN is mutated in 3.12% of lymphoma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

Azd4547, erdafitinib, and trastuzumab emtansine are the most frequent therapies in lymphoma trials with PTEN alterations as inclusion criteria [4].

PTEN is mutated in 3.93% of adenocarcinoma of the gastroesophageal junction patients [3].

PTEN is an inclusion criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open) [4].

Parp inhibitor bgb-290 and tislelizumab are the most frequent therapies in adenocarcinoma of the gastroesophageal junction trials with PTEN alterations as inclusion criteria [4].

PTEN is mutated in 1.7% of mesothelioma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and mesothelioma as inclusion criteria, 1 is phase 2 (1 open) [4].

Niraparib is the most frequent therapy in mesothelioma trials with PTEN alterations as inclusion criteria [4].

PTEN is mutated in 3.46% of hepatocellular carcinoma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and hepatocellular carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PTEN is mutated in 1.45% of peritoneal mesothelioma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for peritoneal mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and peritoneal mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [4].

Pi3k/mtor inhibitor ly3023414, abemaciclib, and cisplatin are the most frequent therapies in peritoneal mesothelioma trials with PTEN alterations as inclusion criteria [4].

PTEN is mutated in 2.0% of osteosarcoma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

Atr kinase inhibitor m6620 is the most frequent therapy in osteosarcoma trials with PTEN alterations as inclusion criteria [4].

PTEN is mutated in 1.33% of thymic carcinoma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for thymic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and thymic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

Akt inhibitor mk2206, erlotinib, and lapatinib are the most frequent therapies in thymic carcinoma trials with PTEN alterations as inclusion criteria [4].

PTEN is mutated in 1.22% of histiocytic and dendritic cell neoplasm patients [3].

PTEN is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

Pi3k/mtor inhibitor ly3023414 is the most frequent therapy in histiocytic and dendritic cell neoplasm trials with PTEN alterations as inclusion criteria [4].

PTEN is mutated in 3.37% of uveal melanoma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for uveal melanoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and uveal melanoma as inclusion criteria, 1 is phase 2 (1 open) [4].

Niraparib is the most frequent therapy in uveal melanoma trials with PTEN alterations as inclusion criteria [4].

PTEN is mutated in 0.89% of pancreatic carcinoma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and pancreatic carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

Vistusertib and selumetinib are the most frequent therapies in pancreatic carcinoma trials with PTEN alterations as inclusion criteria [4].

PTEN is an inclusion criterion in 1 clinical trial for bannayan syndrome, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and bannayan syndrome as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

Everolimus and placebo are the most frequent therapies in bannayan syndrome trials with PTEN alterations as inclusion criteria [4].

PTEN is an inclusion criterion in 1 clinical trial for breast lobular carcinoma in situ, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and breast lobular carcinoma in situ as inclusion criteria, 1 is phase 2/phase 3 (1 open) [4].

Hydroxytyrosol is the most frequent therapy in breast lobular carcinoma in situ trials with PTEN alterations as inclusion criteria [4].

PTEN is an inclusion criterion in 1 clinical trial for cowden syndrome, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and cowden syndrome as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

Everolimus and placebo are the most frequent therapies in cowden syndrome trials with PTEN alterations as inclusion criteria [4].

PTEN is an inclusion criterion in 1 clinical trial for extraskeletal osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and extraskeletal osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for hereditary breast and ovarian cancer syndrome, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and hereditary breast and ovarian cancer syndrome as inclusion criteria, 1 is phase 2/phase 3 (1 open) [4].

Hydroxytyrosol is the most frequent therapy in hereditary breast and ovarian cancer syndrome trials with PTEN alterations as inclusion criteria [4].

PTEN is an inclusion criterion in 1 clinical trial for peritoneal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and peritoneal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

Parp inhibitor bgb-290 and tislelizumab are the most frequent therapies in peritoneal carcinoma trials with PTEN alterations as inclusion criteria [4].

PTEN is an inclusion criterion in 1 clinical trial for pleomorphic rhabdomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and pleomorphic rhabdomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for proteus syndrome, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and proteus syndrome as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

Everolimus and placebo are the most frequent therapies in proteus syndrome trials with PTEN alterations as inclusion criteria [4].